$4.59
5.56% yesterday
Nasdaq, Nov 20, 10:00 pm CET
ISIN
US3441741077
Symbol
FHTX

Foghorn Therapeutics Inc Stock price

$4.59
+0.55 13.61% 1M
+0.45 10.87% 6M
-0.13 2.75% YTD
-3.27 41.60% 1Y
-3.15 40.70% 3Y
-12.34 72.89% 5Y
-11.41 71.31% 10Y
-11.41 71.31% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-0.27 5.56%
ISIN
US3441741077
Symbol
FHTX
Industry

Key metrics

Basic
Market capitalization
$274.8m
Enterprise Value
$94.6m
Net debt
positive
Cash
$180.3m
Shares outstanding
56.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
11.2 | 8.5
EV/Sales
3.9 | 2.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-16.0%
Return on Equity
190.3%
ROCE
-72.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$24.5m | $32.2m
EBITDA
$-83.2m | $-76.9m
EBIT
$-86.5m | $-85.5m
Net Income
$-72.1m | $-68.6m
Free Cash Flow
$-88.9m
Growth (TTM | estimate)
Revenue
-3.9% | 42.4%
EBITDA
15.5% | 20.8%
EBIT
15.0% | 14.7%
Net Income
20.9% | 20.8%
Free Cash Flow
14.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-339.4% | -239.0%
EBIT
-352.9%
Net
-294.2% | -213.2%
Free Cash Flow
-362.5%
More
EPS
$-1.2
FCF per Share
$-1.6
Short interest
2.1%
Employees
112
Rev per Employee
$200.0k
Show more

Is Foghorn Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Foghorn Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Foghorn Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Foghorn Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Foghorn Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
25 25
4% 4%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 27 27
7% 7%
111%
- Research and Development Expense 84 84
15% 15%
342%
-83 -83
16% 16%
-339%
- Depreciation and Amortization 3.29 3.29
2% 2%
13%
EBIT (Operating Income) EBIT -87 -87
15% 15%
-353%
Net Profit -72 -72
21% 21%
-294%

In millions USD.

Don't miss a Thing! We will send you all news about Foghorn Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Foghorn Therapeutics Inc Stock News

Neutral
GlobeNewsWire
15 days ago
Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population  Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and ER+ breast cancer; IND-ready in 2026 Robust preclinical anti-tumor activity and favorable tolerability ...
Neutral
GlobeNewsWire
17 days ago
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jeffe...
Neutral
Seeking Alpha
21 days ago
Foghorn Therapeutics Inc. ( FHTX ) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs October 30, 2025 12:00 PM EDT Company Participants Karin Hellsvik - Chief of Staff to the CEO, VP of Corporate Affairs & Investor Relations Adrian H. Gottschalk - President, CEO & Director Steven Bellon - Chief Scientific Officer Alfonso Quintas-Cardama - Chief Medical Officer Con...
More Foghorn Therapeutics Inc News

Company Profile

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Adrian Gottschalk
Employees 112
Founded 2015
Website foghorntx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today